|
| | Semaglutide Basic information |
| Product Name: | Semaglutide | | Synonyms: | Sermaglutide;Semaglutide (H-7894.0001);semaglutide;Semaglutide impurity;Sermaglutide USP/EP/BP;Sermaglutide CAS 910463 68 2;Ozempic, Rybelsus;Ozempic | | CAS: | 910463-68-2 | | MF: | C187H291N45O59 | | MW: | 4113.57754 | | EINECS: | 203-405-2 | | Product Categories: | GLP;PP;APIs;API;910463-68-2 | | Mol File: | 910463-68-2.mol |  |
| | Semaglutide Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO：3mg/mL (0.73 mM) | | InChIKey | DLSWIYLPEUIQAV-CCUURXOWSA-N |
| | Semaglutide Usage And Synthesis |
| Description | Semaglutide(910463-68-2) is an anti-diabetic medication that is sold under brand names such as Ozempic, Wegovy, and Rybelsus. It is used to treat type 2 diabetes and manage chronic weight. The drug functions similar to human glucagon-like peptide-1 (GLP-1) by increasing insulin secretion, which leads to improved sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen, or as an oral form. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only once-a-week injection is sufficient. | | Uses | Semaglutide is used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. It also works by slowing the movement of food through the stomach and may decrease appetite and cause weight loss. There have been no published reports of hepatotoxicity attributed to semaglutide therapy. | | Definition | ChEBI: Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide. | | Biological Activity | Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM). | | Mechanism of action | Semaglutide is a glucagon-like peptide-1 receptor agonist. It increases the production of insulin, a hormone that lowers the blood sugar level. It also appears to enhance growth of β cells in the pancreas, which are the sites of insulin production. It also inhibits glucagon, which is a hormone that increases blood sugar. It additionally reduces food intake by lowering appetite and slows down digestion in the stomach. In this way it reduces body fat. | | Side effects | Some common side effects of Semaglutide include: nausea, vomiting, diarrhea, abdominal pain, and constipation may occur.
Less common but serious side effects of Semaglutide include: kidney problems, diabetic retinopathy, allergic reactions, low blood sugar, and pancreatitis.
In people with heart problems, it can cause damage to the back of the eye (retinopathy). If you experience any of these serious side effects, contact your healthcare provider immediately.
www.mayoclinic.org | | in vitro | Semaglutide is selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) is three-fold decreased compared to liraglutide, whereas the albumin affinity is increased. | | in vivo | The plasma half-life is 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. |
| | Semaglutide Preparation Products And Raw materials |
|
